NTNathan Y. Tat

Nathan Y. Tat

*This is an algorithmically generated author record based on publicly available information.

Nathan Y. Tat has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study

    by Vivian Y. Tat, Pinghan Huang, Kamil Khanipov, Nathan Y. Tat, Chien-Te Kent Tseng, George Golovko

    Coronavirus disease 2019 (COVID-19) continues to cause morbidity and mortality worldwide; therefore, effective treatments remain crucial to controlling it. As interferon-alpha (IFN-α) and -beta (β) have been proposed as COVID-19 treatments, we sought to assess their effectiveness on respiratory, cardiovascular, neurological, and psychiatric signs and symptoms, as well as PASC and death, in hospitalized COVID-19 patients without multiple sclerosis (MS). Using a federated data research network (TriNetX), we performed a retrospective cohort study of hospitalized COVID-19 patients without MS who received IFN-α or -β treatment, comparing them to a similar cohort who did not receive treatment. Following propensity-score matched analyses, we demonstrate that hospitalized COVID-19 patients who were treated with IFN-α or -β had significantly higher odds of death. In contrast, there was no significant difference in any other outcomes between 1–30 days or 1 day to anytime afterward. Overall, hospitalized COVID-19 patients without MS who were treated with IFN-α or -β had similar short- and long-term sequelae (except for mortality) as those who did not receive treatment. The potential benefits of utilizing IFN-α or -β treatment as therapeutics remain to be realized, and our research highlights the need to explore repurposing drugs for COVID-19 using real-world evidence.


  • Open Access

    Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study

    by Vivian Y. Tat, Pinghan Huang, Kamil Khanipov, Nathan Y. Tat, Chien-Te Kent Tseng, George Golovko

    Coronavirus disease 2019 (COVID-19) continues to cause morbidity and mortality worldwide; therefore, effective treatments remain crucial to controlling it. As interferon-alpha (IFN-α) and -beta (β) have been proposed as COVID-19 treatments, we sought to assess their effectiveness on respiratory, cardiovascular, neurological, and psychiatric signs and symptoms, as well as PASC and death, in hospitalized COVID-19 patients without multiple sclerosis (MS). Using a federated data research network (TriNetX), we performed a retrospective cohort study of hospitalized COVID-19 patients without MS who received IFN-α or -β treatment, comparing them to a similar cohort who did not receive treatment. Following propensity score-matched analyses, we demonstrate that hospitalized COVID-19 patients who were treated with IFN-α or -β had significantly higher odds of death. In contrast, there was no significant difference in any other outcomes between 1-30 days or 1 day to anytime afterward. Overall, hospitalized COVID-19 patients without MS who were treated with IFN-α or -β had similar short- and long-term sequelae (except for mortality) as those who did not receive treatment. The potential benefits of utilizing IFN-α or -β treatment as therapeutics remain to be realized, and our research highlights the need to explore repurposing drugs for COVID-19 using real-world evidence.


  • The US Space Program's Path Forward for Low-Earth Orbit (LEO) after Decommissioning of the International Space Station (ISS)

    by Nathan Tat, Vivian Tat, Candise Tat

    As activities in space rapidly evolve, the International Space Station (ISS) is approaching its retirement date. Since decommissioning of the ISS is scheduled for 2030, the United States (US) must identify paths forward for space station operations in low-earth orbit (LEO). Having a manned LEO space station after the conclusion of the ISS program will allow the US to continue possessing a platform to conduct scientific research, advance technology, and investigate the effects of microgravity on biological physiology. Options to continue LEO operations include having private entities construct and operate commercial space stations, reusing components of the ISS, directing NASA to spearhead efforts in building a new space station, or abandoning US-led space stations in LEO altogether. We recommend that commercial firms build and operate space stations, permitting multiple platforms to be created while maintaining the legacy of the ISS. The US will have facilities in LEO for research and development, thus advancing technological and scientific knowledge for Earth-based applications and future space missions.